Mads Clausen

Mads Clausen led the establishment of MC2 Therapeutics and serves as Chairman of the Board. Mr. Clausen is also Executive Chairman of Vandstrom, Inc. (US), a privately held developer of novel high-performance membrane technology. Further to this, he serves as a Director of the Board of the Bitten and Mads Clausen Foundation (Denmark). Mr. Clausen holds a MS in Engineering from the Technical University of Denmark, MS in Biotechnology from The Johns Hopkins University and an MBA from the London Business School.

Anders D. Hove, M.D.

Anders D. Hove is a managing partner at Majalin/Amzak Health, a partnership focusing on long-term investments in biotech, specialty pharma and medical device companies. Mr. Hove was most recently a managing general partner at Venrock Associates (“Venrock”), a venture capital firm, which he joined in 2004 focusing on private and public biotech investments. In 2008, Mr. Hove founded Venrock Healthcare Capital Partners, Venrock’s public fund focused on small capitalization biotech companies and late-stage private companies. From 1996 to 2003 he was a fund manager at BB Biotech, a multi-billion $ investment firm focused on public and private biotech investment, and from 2002 to 2003 Mr. Hove served as Chief Executive Officer of Bellevue Asset Management AG and as manager of BB Biotech. Mr. Hove has completed numerous structured public investments, 22 investments in private biotech or medtech companies and has served on 19 Boards. 14 of his private investments have completed an IPO and 4 companies were acquired while private. Some of the private or small cap public investments which Mr. Hove led or provided substantial contributions to include Adnexus, Alexion, Anacor, Arena, Ascendis, Aviron, Biomarin, Coherus, Dyax, Edge, Eyetech, GW Pharma, Medimmune, Neurocrine, Peak Surgical, Radius, Stemline, Tesaro, The Medicines Company, Theravance, etc. Mr. Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba-Geigy. He is currently a member of the board of directors of a number of public and private companies.

Mr. Hove received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, a M.D. from the University of Copenhagen and a M.B.A. from INSEAD in France.

John Haurum, M.D., D.Phil.

John Haurum is a Non-executive Director in European biotech companies Adcendo, Agomab, CatalYm, MC2 Therapeutics, Neophore, Solid Therapeutics, Storm and Synklino. He was the CEO of F-star in Cambridge, UK (2012-2018), where he built a successful biotech company that initiated two clinical trials in oncology and generated more than €200M in non-dilutive revenue. Previously, Mr. Haurum was VP Research at ImClone Systems, New York (2010-2012) and cofounder and Chief Scientific Officer of Symphogen A/S, Denmark (2000-2009). After graduating in Medicine in Aarhus Denmark 1992, Mr. Haurum received a D.Phil. in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England. Subsequently, he took up positions as Associate Professor at the Danish Cancer Society and completed his medical training.

Tomas Dahl Mikkelsen